Straits Times Index
3,286.33 +15.35 (+0.47%) S&P 500
4,210.24 +87.77 (+2.13%) Dow
33,309.51 +535.11 (+1.63%) Nasdaq
12,854.80 +360.88 (+2.89%) BTC-USD
23,951.39 +756.12 (+3.26%) CMC Crypto 200
559.85 +28.63 (+5.39%)
Endo International plc (ENDP)
After hours:
| Previous close | 0.4030 |
| Open | 0.4200 |
| Bid | 0.4300 x 3100 |
| Ask | 0.4379 x 2200 |
| Day's range | 0.3800 - 0.4400 |
| 52-week range | 0.2800 - 7.0700 |
| Volume | |
| Avg. volume | 51,667,903 |
| Market cap | 101.71M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.1110 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.33 |
- Zacks
Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates
Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- CNW Group
ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS
Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022.
- CNW Group
Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy
Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today that Health Canada has accepted its New Drug Submission (NDS) for cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. A decision from Health Canada as to whether cenobamate tablets can be marketed and sold in Canada under this NDS is expected mid-2023.
